

Julio D Duarte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2282528/publications.pdf>

Version: 2024-02-01

29
papers

876
citations

623574

14
h-index

501076

28
g-index

29
all docs

29
docs citations

29
times ranked

1337
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β -blockers. <i>Pharmacogenomics Journal</i> , 2022, 22, 62-68.	0.9	3
2	β -receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery. <i>Clinical and Translational Science</i> , 2022, 15, 619-625.	1.5	3
3	Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. <i>Pharmacogenomics</i> , 2022, 23, 85-95.	0.6	1
4	CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. <i>Journal of the American Heart Association</i> , 2022, 11, e024159.	1.6	24
5	IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. <i>Blood</i> , 2021, 137, 1208-1218.	0.6	22
6	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	2.3	25
7	County-level longitudinal clustering of COVID-19 mortality to incidence ratio in the United States. <i>Scientific Reports</i> , 2021, 11, 3088.	1.6	25
8	Pharmacogenetics to guide cardiovascular drug therapy. <i>Nature Reviews Cardiology</i> , 2021, 18, 649-665.	6.1	49
9	Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines. <i>Clinical and Translational Science</i> , 2021, 14, 1841-1852.	1.5	6
10	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e020633.	1.6	13
11	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. <i>Genetics in Medicine</i> , 2021, 23, 2335-2341.	1.1	32
12	Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects. <i>Frontiers in Genetics</i> , 2021, 12, 701405.	1.1	2
13	NR3C2 Genotype is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldo-DHF Trial. <i>Pharmacotherapy</i> , 2021, , .	1.2	7
14	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , 2020, 20, 724-735.	0.9	25
15	Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue. <i>Clinical and Translational Science</i> , 2019, 12, 416-423.	1.5	5
16	Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 75, 1.	0.8	2
17	Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension. <i>Scientific Reports</i> , 2019, 9, 19572.	1.6	11
18	CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 974-982.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674.	2.3	94
20	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	10
21	Multisite Investigation of Outcomes With Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	1.1	213
22	Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1670.	3.8	25
23	Genome-Wide Analysis Identifies <i>IL-18</i> and <i>FUCA2</i> as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease. <i>PLoS ONE</i> , 2016, 11, e0163013.	1.1	11
24	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1944-1954.	0.5	34
25	Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 692-699.	0.7	13
26	Genes affecting warfarin response—interactive or additive?. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 258-260.	1.0	3
27	Epigenetics Primer: Why the Clinician Should Care About Epigenetics. <i>Pharmacotherapy</i> , 2013, 33, 1362-1368.	1.2	16
28	Lack of association between polymorphisms in <i>STK39</i> , a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 516-519.	0.7	15
29	Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 793-802.	0.6	175